Literature DB >> 50417

[Long-term treatment with L-DOPA in a case of torsion dystonia (authors transl)].

W Winkelmann.   

Abstract

A 36-year old woman had been able to move from place to place only by crawling until 1971 after she had been treated with L-DOPA, the dose of which was increased to a maximum of 2.5 g daily. Within 4 weeks there was a diminution of her increased muscle tone and she experienced a dramatic improvement in her daily living activities, being able to walk without assistance for the first time in 20 years. This improvement has continued with a daily maintenance dose of 1.25 g. For patients with torsion dystonia, where the so-called myostatic component preponderates, cautious application of L-DOPA seems to be justified and further clinical studies are suggested.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50417     DOI: 10.1007/bf00312807

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Parkinsonism and DOPA.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene; R B Aronson
Journal:  Trans Assoc Am Physicians       Date:  1968

2.  Metabolic modification of some neurologic disorders.

Authors:  G C Cotzias
Journal:  JAMA       Date:  1969-11-17       Impact factor: 56.272

3.  Neurosurgical treatment of dystonia.

Authors:  I S Cooper
Journal:  Neurology       Date:  1970-11       Impact factor: 9.910

4.  Biochemical and pharmacologic studies of dystonia.

Authors:  T N Chase
Journal:  Neurology       Date:  1970-11       Impact factor: 9.910

5.  Preliminary remarks on the L-dopa therapy of dystonia.

Authors:  M Coleman
Journal:  Neurology       Date:  1970-11       Impact factor: 9.910

6.  Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.

Authors:  O D Hornykiewicz
Journal:  Neurology       Date:  1970-12       Impact factor: 9.910

7.  Pathology of the torsion dystonias (dystonia musculorum deformans).

Authors:  W Zeman
Journal:  Neurology       Date:  1970-11       Impact factor: 9.910

8.  [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr       Date:  1962

9.  Rationale for the use of L-dopa in the torsion dystonias.

Authors:  A Barbeau
Journal:  Neurology       Date:  1970-11       Impact factor: 9.910

10.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.